These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. ONC201 induces the unfolded protein response (UPR) in high- and low-grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity. Rumman M; Buck S; Polin L; Dzinic S; Boerner J; Winer IS Cancer Med; 2021 May; 10(10):3373-3387. PubMed ID: 33932119 [TBL] [Abstract][Full Text] [Related]
14. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer. Garrett LA; Growdon WB; Rueda BR; Foster R J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667 [TBL] [Abstract][Full Text] [Related]
15. miRNA-301b-3p accelerates migration and invasion of high-grade ovarian serous tumor via targeting CPEB3/EGFR axis. Liu F; Zhang G; Lv S; Wen X; Liu P J Cell Biochem; 2019 Aug; 120(8):12618-12627. PubMed ID: 30834603 [TBL] [Abstract][Full Text] [Related]
16. A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Marchion DC; Bicaku E; Xiong Y; Bou Zgheib N; Al Sawah E; Stickles XB; Judson PL; Lopez AS; Cubitt CL; Gonzalez-Bosquet J; Wenham RM; Apte SM; Berglund A; Lancaster JM Oncol Rep; 2013 May; 29(5):2011-8. PubMed ID: 23467907 [TBL] [Abstract][Full Text] [Related]
17. The role of KIF14 in patient-derived primary cultures of high-grade serous ovarian cancer cells. Thériault BL; Cybulska P; Shaw PA; Gallie BL; Bernardini MQ J Ovarian Res; 2014 Dec; 7():123. PubMed ID: 25528264 [TBL] [Abstract][Full Text] [Related]
18. Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy. Chen P; Huhtinen K; Kaipio K; Mikkonen P; Aittomäki V; Lindell R; Hynninen J; Auranen A; Grénman S; Lehtonen R; Carpén O; Hautaniemi S Cancer Res; 2015 Aug; 75(15):2987-98. PubMed ID: 26122843 [TBL] [Abstract][Full Text] [Related]
19. Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response. Zervantonakis IK; Iavarone C; Chen HY; Selfors LM; Palakurthi S; Liu JF; Drapkin R; Matulonis U; Leverson JD; Sampath D; Mills GB; Brugge JS Nat Commun; 2017 Aug; 8(1):365. PubMed ID: 28848242 [TBL] [Abstract][Full Text] [Related]
20. Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer. Erriquez J; Olivero M; Mittica G; Scalzo MS; Vaira M; De Simone M; Ponzone R; Katsaros D; Aglietta M; Calogero R; Di Renzo MF; Valabrega G Oncotarget; 2016 May; 7(18):26181-91. PubMed ID: 27027433 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]